Market Overview

Teva 'Disappointed' In Court's Patent Decision

Teva 'Disappointed' In Court's Patent Decision

In the latest development in the court battle between Eli Lilly And Co (NYSE: LLY) and Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) over an Alimta patent, the U.S. Court of Appeals ruled that Teva was liable for inducing patent infringement by physicians.

This decision supported that of a lower court, which issued a ruling in August 2015 granting Teva five years of exclusive ownership of the cancer drug.

"We are disappointed with the Court's decision," a Teva spokesperson told Benzinga.

For Eli Lilly, the victory was a positive turning point in its battle against patent infringements. The company previously lost its fight for exclusive rights to Alimta in the European Union.

Eli Lilly shares were up 2 percent at $76.96, while Teva shares were down 0.23 percent on Thursday.

Posted-In: AlimtaNews Health Care Legal Exclusives General Best of Benzinga


Related Articles (TEVA + LLY)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at